Melanoma

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

By

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

By

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

By

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

More Than Half of Melanomas Are Self-Detected, Especially by Women

More Than Half of Melanomas Are Self-Detected, Especially by Women

More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

By

A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

By

Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.

Experimental Drug Shows Promise in Melanoma Treatment

Experimental Drug Shows Promise in Melanoma Treatment

Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

By

Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.

Study Supports Use of PD-1 Inhibitors in Acral, Mucosal Melanomas

By

Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

By

Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.

Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

By

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

By

Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.

Study Better Characterizes Immunotherapy-related Skin Toxicities

By

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

De Novo Melanomas May Be More Aggressive Than Nevus-associated Lesions

By

De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

By

In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

By

Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

By

PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.

Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma

By

A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.

Soles of the Feet Should Also Be Checked for Skin Cancer

Soles of the Feet Should Also Be Checked for Skin Cancer

Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

By

Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.

Modified Thiazole Benzenesulfonamide Demonstrates Anticancer Activity in Melanoma

By

A newly discovered synthesized drug reduced the viability of melanoma cells without affecting normal cells in cell culture and mouse xenograft models of the disease. The drug, HA15, is a type of thiazole benzenesulfonamide.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

By

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

By

At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

By

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

By

Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

By

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

By

Combining radiation treatments with a new generation of immunotherapies is showing promise in the treatment of melanoma, according to a recent review.

Liquid Biopsy Found Comparable to Standard Tissue Biopsy in Identifying BRAF V600 Mutation Status

By

Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs